Christine M. Albert, MD, MPH
Professor of Medicine, Harvard Medical School
Physician, Brigham and Women’s Hospital
calbert@bwh.harvard.edu
Dr. Albert is the Director of the Center for Arrhythmia Prevention at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. Dr. Albert received her MD from Harvard Medical School and MPH from the Harvard School of Public Health. She completed her Internal Medicine, Cardiology, and Cardiac Electrophysiology training at the Massachusetts General Hospital in Boston. She currently holds joint appointments as a clinical cardiac electrophysiologist and epidemiologist within the Divisions of Cardiovascular and Preventive Medicine at Brigham and Women’s Hospital. Dr. Albert is currently the Principal Investigator on two NIH-sponsored R01s, and her research focuses on epidemiology, risk stratification, and prevention of sudden cardiac death and atrial fibrillation in large prospective cohort designs and in multi-center clinical studies, most notably seminal contributions regarding the contribution of diet, lifestyle, and genetics to the burden of heart rhythm disorders. Dr. Albert serves on the editorial boards of Heart Rhythm and is the President-Elect of the Heart Rhythm Society. Effective September 1, 2019, Dr. Albert has joined Cedars-Sinai Medical Center as the founding Chair of the Department of Cardiology and the Lee and Harold Kapelovitz Endowed Chair in Research Cardiology.
BA: Boston University
MD: Harvard Medical School
MPH: Harvard School of Public Health
Full Listing of Publications
- Coronary atherosclerosis in athletes: emerging concepts and preventive strategies January 10, 2025There should be no assumption that an athlete is immune to coronary artery disease (CAD), even when traditional cardiovascular (CV) risk factors appear well-managed. Excelling in certain aspects of health does not equate to total CV protection. Recent data from cardiac imaging studies have raised the possibility that long-term, high-volume, high-intensity endurance exercise is associated […]Guido Claessen
- Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial January 8, 2025Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) […]Nicholas A Vitanza
- Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement December 27, 2024Trends in diagnostic biopsy sample collection approaches for primary bone sarcomas have shifted in the past 2 decades. Although open/incisional biopsies used to be the predominant approach to obtain diagnostic material for Ewing sarcoma and osteosarcoma, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and […]Matthew S Dietz
- Advances in cellular therapies for children and young adults with solid tumors December 19, 2024PURPOSE OF REVIEW: Adoptive immunotherapy brings hope to children and young adults diagnosed with high-risk solid tumors. Cellular (cell) therapies such as chimeric antigen receptor (CAR) T cell, CAR natural killer (NK) cell, and T cell receptor (TCR) T cell therapy are potential avenues of targeted therapy with limited long-term toxicities. However, development of cell […]Michelle Choe
- Clinical RNA sequencing clarifies variants of uncertain significance identified by prior testing November 1, 2024CONCLUSION: Clinical RNA-seq can clarify VUS, especially splice variants, but laboratory-specific interpretation guidelines may lead to indeterminate results. Identifying individuals likely to benefit from RNA-seq and providing appropriate counseling poses unique challenges.Jonathan Marquez